2. Academic Validation
  3. Efficient large-scale expansion of cord blood-derived NK cells: leveraging lipopolysaccharide for enhanced NK cell production

Efficient large-scale expansion of cord blood-derived NK cells: leveraging lipopolysaccharide for enhanced NK cell production

  • Cytotherapy. 2025 Jun;27(6):782-789. doi: 10.1016/j.jcyt.2025.02.006.
Hataiwan Kunkanjanawan 1,  Sirilak Somredngan 2,  Tanut Kunkanjanawan 3,  Patompon Wongtrakoongate 4,  Wannida Wongsakmanee 5,  Veerapol Khemarangsan 6,  Jun-Ichi Masuyama 7,  Rangsun Parnpai 8
Affiliations

Affiliations

  • 1 Embryo Technology and Stem Cell Research Center, School of Biotechnology, Suranaree University of Technology, Nakhon Ratchasima, Thailand; Medeze Research and Development Co., Ltd., Nakhon Pathom, Thailand. Electronic address: hataiwan@medezegroup.com.
  • 2 Medeze Group Public Company Limited, Nakhon Pathom, Thailand. Electronic address: sirilak@medezegroup.com.
  • 3 Medeze Group Public Company Limited, Nakhon Pathom, Thailand. Electronic address: tanut@medezegroup.com.
  • 4 Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand; Center for Neuroscience, Faculty of Science, Mahidol University, Bangkok, Thailand. Electronic address: patompon.won@mahidol.ac.th.
  • 5 Division of Obstetrics and Gynecology, Suranaree University Hospital, Nakhon Ratchasima, Thailand. Electronic address: freezepreal@gmail.com.
  • 6 Medeze Group Public Company Limited, Nakhon Pathom, Thailand. Electronic address: veerapol@medezegroup.com.
  • 7 New City Osaki Clinic, Tokyo, Japan. Electronic address: jmas@nco-clinic.jp.
  • 8 Embryo Technology and Stem Cell Research Center, School of Biotechnology, Suranaree University of Technology, Nakhon Ratchasima, Thailand. Electronic address: rangsun@g.sut.ac.th.
PMID: 40057889 DOI: 10.1016/j.jcyt.2025.02.006
Abstract

Growing research in the immunotherapy field has shed light on the adoptive cell transfer efficacy of ex vivo expanded natural killer (NK) cells in Cancer treatment. In accordance with the advantages of using cord blood as a source of hematopoietic cells, this study aimed to establish a sustainable supply of NK cells by developing a simple method for expanding cord blood-derived NK (CBNK) cells without using feeders or cell-sorting processes. To achieve this aim, culture strategies that stimulate the proliferation of NK cells from hematopoietic stem and progenitor cells (HSPCs) would result in a high purity of CBNK cells. Here, we first compared the potential of lipopolysaccharide (LPS) and the Notch signaling agonist Yhhu-3792 to promote CBNK cell proliferation in cytokine-based conditions before applying these findings to a large-scale expansion platform. Overall, we reveal that the presence of LPS at 1 µg/mL during the first week of a 21-day expansion protocol resulted in an average total nucleated cell (TNC) count of 1.68 ± 2.92 × 1010, with 92.09 ± 3.47% of the expanded cells being NK cells (n = 5). All subsequent analyses demonstrated that the expanded CBNK cells produced by this procedure are phenotypically and functionally competent NK cells. Collectively, this study developed a simple cytokine-based and cell-sorting-free method for the large-scale expansion of CBNK cells.

Keywords

Notch signaling agonist; adoptive cell therapy; cord blood-derived natural killer cells; large-scale expansion; lipopolysaccharide; natural killer cells.

Figures
Products